Home About Us Company Profile Axxam Philosophy People Facilities Quality and HSE Partners and Participated Companies Publications Grants Posters Legislative Decree no. 231/2001 Discovery Services Discovery Services Cell-based Assays Biochemical Assays High-Throughput Screening Compound Collections Compound Management Ready-to-go Assays Hit follow-up and Electrophysiology Safety and Liability Profiling Technologies Discovery Programs Discovery Programs Careers Working at Axxam Job Listing News Contacts Contacts Contact Us Reach Us Select Page Axxam is an innovative Partner Research Organization (iPRO). We are a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural) or those provided by our clients, compound management, hit identification and hit validation. Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures. Discovery Services Cell-based Assay Development Biochemical Assay Development High-Throughput Screening Hit Follow-up and Electrophysiology Compound Collections Ready-to-go Assays Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain Milan (Italy), 20 September 2018 Axxam is proud to announce its participation to a consortium of international partners, held by the Danish... Read More Axxam SpA is a member of the RESOLUTE consortium Axxam SpA is a member of the RESOLUTE consortium Milan, 4th July 2018. Axxam is proud to announce its participation to the RESOLUTE (Research empowerment on solute carriers) consortium, a public-private research partnership supported by the Innovative Medicines... Read More Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio May 14th, 2018 - Milan (Italy) - Axxam is proud to announce that Acousia Therapeutics (Tubingen; Germany), a biotech company participated by Axxam and focused to... Read More Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases April 24th 2018 - Milan (Italy) - Axxam S.p.A. announced today a collaboration with GenSight Biologics S.A. in... Read More AXXAM expands its natural products service business AXXAM expands its natural products service business Thursday 22nd March 2018, Milan - Axxam SpA (“AXXAM”) announces today the acquisition of all shares of IMAX Discovery GmbH (“IMAX Discovery”) held by IMD Natural Solutions GmbH (“INS”) to make IMAX Discovery a... Read More Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain and inflammation Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain and inflammation January 10th 2018 - Milan (Italy) and Cambridge (UK) - Axxam S.p.A. and Proximagen Ltd. today announced a strategic... Read More Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round January 4th, 2018 - Milan (Italy) - Axxam is proud to announce that Rewind Therapeutics, a Belgian biotech company recently founded by... Read More leadXpro and Axxam enter collaboration on a GPCR lead discovery project leadXpro and Axxam enter collaboration on a GPCR lead discovery project Milan, Italy, & Villigen, Switzerland, 1st of November 2017 - Axxam SpA and leadXpro AG announce today a collaboration for the discovery of novel small molecule lead compounds for a newly... Read More Axxam consolidates its collaboration with Genedata Axxam consolidates its collaboration with Genedata September 27, 2017 - Axxam is glad to announce that the fruitful collaboration with Genedata, a leading provider of advanced software solutions for R&D, has been strengthened by the extension of the license for... Read More Axxam Enters Into Research Collaboration with Sanofi in the Field of Neurodegeneration Axxam Enters Into Research Collaboration with Sanofi in the Field of Neurodegeneration September 5 2017 - Milan (Italy) - Axxam S.p.A today announced the start of a research collaboration with Sanofi designed to further optimize a number of lead series of small... Read More Subscribe to Our Newsletter Success! Subscribe Follow us on Privacy Policy Cookie Policy Disclaimer info@axxam.com AXXAM S.p.A.- Openzone - Via Meucci, 3 - 20091 Bresso - Milan, Italy - Cap. Soc.: euro 126.667 i.v. - C.F./P.Iva/Vat IT13451210150 - R.E.A. Milan 1653022 We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject Read More